Document is current
Any future updates will be listed below
-
Authors
Wójcik, Zuzanna https://orcid.org/0009-0007-6214-7736
Dimitrova, Vania https://orcid.org/0000-0002-7001-0891
Warrington, Lorraine https://orcid.org/0000-0002-8389-6134
Velikova, Galina https://orcid.org/0000-0003-1899-5942
Absolom, Kate https://orcid.org/0000-0002-5477-6643
-
Funding
Funding for this research was provided by:
UK Research and Innovation (EP/S024336/1, EP/S024336/1, EP/S024336/1, EP/S024336/1, EP/S024336/1)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 25 March 2025
First Online: 11 April 2025
Declarations
:
: Not applicable.
: Galina Velikova: Honoraria: Pfizer, Novartis, Eisai, Lilly Advisory boards: Consultancy fees from AstraZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi April 2024 = AZ working group (unpaid) Institutional grant: Pfizer.
